Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease

Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease

Stephen L. Atkin, Manaf AlQahtani, Abdulkarim Abdulrahman, Abdulrahman Almadani, Salman Yousif Alali, Alaa Mahmood Al Zamrooni, Amal Hamza Hejab, Ronán M. Conroy, Pearl Wasif, Sameer Otoom, Manal Abduljalil

Abstract Convalescent plasma (CP) therapy in COVID-19 disease may improve clinical outcome in severe disease. This pilot study was undertaken to inform feasibility and safety of further definitive studies. This was a prospective, interventional and randomized open label pilot trial in patients with severe COVID-19. Twenty COVID-19 patients received two 200 ml transfusions of convalescent patient CP over 24-h compared with 20 who received standard of care. The primary outcome was the requirement for ventilation (non-invasive or mechanical ventilation). The secondary outcomes were biochemical parameters and mortality at 28 days. The CP group were a higher risk group with higher ferritin levels (p 

2021

10.1038/s41598-021-89444-5

Epidemiology and Health

Korean Society of Epidemiology

Science, Medicine